Allogeneic stem cell transplantation for chronic myeloid leukemia

Seminars in Hematology

Volumn 40, Issue 1, 2003, Pages 59-71

  Barrett, John ^a,b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CYCLOPHOSPHAMIDE; IMATINIB;

BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0037255789     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(03)70043-2     Document Type: Review

References (98)

1. Alyea EP, Soiffer RJ, Canning C, et al: Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 91:3671-3680, 1998
2. Barrett AJ, van Rhee F: Graft-versus-leukaemia. Baillieres Clin Haematol 10:337-355, 1997
3. Barrett AJ: Mechanisms of the graft-vs-leukemia reaction. Stem Cells 15:248-258, 1997
4. Barrett AJ, Mavroudis D, Tisdale J, et al: T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft versus-leukemia effect. Bone Marrow Transplant 21:543-551, 1998
5. Barrett AJ, Ringden O, Zhang MJ, et al: Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. Blood 95:3323-3327, 2000
6. Barta A, Denes R, Masszi T, et al: Remarkably reduced transplant-related complications by dibromomannitol nonmyeloablative conditioning before allogeneic bone marrow transplantation in chronic myeloid leukemia. Acta Haematol 105:64-70, 2001
7. Beelen DW, Elmaagacli AH, Schaefer UW: The adverse influence of pretransplant interferon-alpha (IFN-alpha) on transplant outcome after marrow transplantation for chronic phrase chronic myelogenous leukemia increases with the duration of IFN-alpha exposure. Blood 93:1779-1790, 1999
8. Brandenburg U, Gottlieb D, Bradstock K: Antileukemic effects of rapid cyclosporin withdrawal in patients with relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Leuk Lymphoma 31:545-550, 1998
9. Carreras E, Tomas JF, Sanz G, et al: Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: the Spanish experience. The Chronic Myeloid Leukemia Subcommittee of the GETH. Grupo Espanol de Trasplante Hemopoyetico. Haematologica 85:530-538, 2000
10. Champlin R, Khouri I, Shimoni A, et al: Harnessing graft-versus-malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 111:18-29, 2000
11. Childs R, Epperson D, Bahceci E, et al: Molecular remission of chronic myeloid leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant: in vivo and in vitro evidence for a graft-versus-leukaemia effect. Br J Haematol 107:396-400, 1999
12. Clark RE, Dodi IA, Hill SC, et al: Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 98:2887-2893, 2001
13. Clave E, Molldrem J, Hensel N, et al: Donor-recipient polymorphism of the proteinase 3 gene: a potential target for T-cell alloresponses to myeloid leukemia. Immunotherapy 22:1-6, 1999
14. Clift RA, Buckner CD, Thomas ED, et al: Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84:2036-2043, 1994
15. Craddock C, Szydlo RM, Dazzi F, et al: Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: The case for tailored graft-versus-host disease prophylaxis. Br J Haematol 112:228-236, 2001
16. Craddock C, Szydlo RM, Klein JP, et al: Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. Blood 96:86-90, 2000
17. Davies SM, DeFor TE, McGlave PB, et al: Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med 110:404-405, 2001
18. Devergie A, Apperley JF, Labopin M, et al: European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 20:11-19, 1997
19. Dini G, Lamparelli T, Rondelli R, et al: Unrelated donor marrow transplantation for chronic myelogenous leukaemia. Br J Haematol 102:544-552, 1998
20. Drobyski WR, Hessner MJ, Klein JP, et al: T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. Blood 94:434-441, 1999
21. Elmaagacli AH, Beelen DW, Opalka B, et al: The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow. Blood 94:381-383, 1999
22. Elmaagacli AH, Beelen DW, Trenn G, et al: Induction of a graft-versus leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 23:771-777, 1999
23. Elmaagacli AH, Runkel K, Steckel N, et al: A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase. Bone Marrow Transplant 27:809-815, 2001
24. Elmaagacli AH, Basoglu S, Peceny R, et al: Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 99:1130-1135, 2002
25. Falkenburg JH, Smit WM, Willemze R: Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia. Immunol Rev 157:223-230, 1997
26. Falkenburg JH, Wafelman AR, Joosten P, et al: Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 94:1201-1208, 1999
27. Gale RP, Horowitz MM, Ash RC, et al: Identical-twin bone marrow transplants for leukemia. Ann Intern Med 120:646-52, 1994
28. Gao L, Bellantuono I, Elsasser A, et al: Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95:2198-2203, 2000
29. Gardiner N, Lawler M, O'Riordan JM, et al: Monitoring of lineage-specific chimaerism allows early prediction of response following donor lymphocyte infusions for relapsed chronic myeloid leukaemia. Bone Marrow Transplant 21:711-719, 1998
30. +-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Graft vs. leukemia without graft vs. host disease. Blood 86:4337-4343, 1995
31. Giralt S, O'Brien S, Talpaz M, et al: Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation. Cytokines Mol Ther 1:115-122, 1995
32. Giralt S, Thall PF, Khouri I, et al: Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97:631-637, 2001
33. Gratwohl A, Hermans J, van Biezen A, et al: Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia. Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 95:494-500, 1996
34. Griesshammer M, Arnold R, Bangerter M, et al: Chronic myeloid leukemia in accelerated phase: treatment results with conventional chemotherapy and allogeneic bone marrow transplantation in 96 patients. Eur J Haematol 61:7-13, 1998
35. Hansen JA, Gooley TA, Martin PJ, et al: Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338:962-968, 1998
36. Hartman AR, Williams SF, Dillon JJ. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: A meta-analysis. Bone Marrow Transplant 22:439-443, 1998
37. Hehlmann R, Hochhaus A, Kolb HJ, et al: Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood 94:3668-3677, 1999
38. Hessner M, Endean D, Casper J, et al: Use of unrelated marrow grafts compensates for reduced graft versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Blood 86:3987-3896, 1995
39. Higano CS, Chielens D, Raskind W, et al: Use of α-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation. Blood 90:2549-2554, 1997
40. Horowitz MM, Gale RP, Sondel PM, et al: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555-562, 1990
41. Horowitz MM: Summary slides. IBMTR Newsletter 9:4-11, 2002
42. Jabro G, Koc Y, Boyle T, et al: Role of splenic irradiation in patients with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 6:211-213, 2000
43. Jiang YZ, Barrett AJ, Goldman JM, et al: Evidence for natural killer cell modulation of a graft-versus-graft-versus-leukaemia effect without graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol 74:1-6, 1997
44. Kaeda J, Chase A, Goldman JM: Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia. Acta Haematol 107:64-75, 2002
45. Kim I, Park S, Kim BK, et al: Allogeneic bone marrow transplantation for chronic myeloid leukemia: A retrospective study of busulfan-Cytoxan versus total body irradiation-Cytoxan as preparative regimen in Koreans. Clin Transplant 15:167-172, 2001
46. Kitzis A, Brizard F, Dascalescu C, et al: Persistence of transcriptionally silent BCR-ABL rearrangements in chronic myeloid leukemia patients in sustained complete cytogenetic remission. Leuk Lymphoma 42:933-944, 2001
47. Kolb H-J, Mitmuller J, Clemm Ch, et al: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462-2465, 1990
48. Kolb HJ, Schattenberg A., Goldman JM, et al: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041-2050, 1995
49. Konstantinidou P, Szydlo RM, Chase A, et al: Cytogenetic status pre-transplant as a predictor of outcome post bone marrow transplantation for chronic myelogenous leukaemia. Bone Marrow Transplant 25:143-146, 2000
50. Kroger N, Zabelina T, Kruger W, et al: Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients. Bone Marrow Transplant 27:349-354, 2001
51. Lee SJ, Klein JP, Anasetti C, et al: The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. Blood 98:3205-3211, 2001
52. Mackinnon S, Papadopoulos E, Carabasi M, et al: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus host disease. Blood 86:1261-1268, 1995
53. McGlave PB, Shu XO, Wen W, et al: Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood 95:2219-2225, 2000
54. McSweeney PA, Niederwieser D, Shizuru JA, et al: Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390-3400, 2001
55. Mehta J, Powles R, Kulkarni S, et al: Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients. Bone Marrow Transplant 20:129-135, 1997
56. Molldrem JJ, Lee PP, Wang C, et al: A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res 59:2675-2681, 1999
57. Molldrem JJ, Lee PP, Wang C, et al: Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6:1018-1023, 2000
58. Morariu-Zamfir R, Rocha V, Devergie A, et al: Influence of CD34(+) marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukaemia. Bone Marrow Transplant 27:575-580, 2001
59. Morton AJ, Gooley T, Hansen JA, et al: Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood 92:394-3401, 1998
60. Mutis T, Gillespie G, Schrama E, et al: Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med 5:839-842, 1999
61. Novitzky N, Rubinstein R, Hallett JM, et al: Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia: A therapeutic strategy. Transplantation 69:1358-1363, 2000
62. Olavarria E, Kanfer E, Szydlo R, et al: Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 97:1560-1565, 2001
63. Olavarria E, Craddock C, Dazzi F, et al: Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood 99:3861-3862, 2002
64. Pigneux A, Tanguy ML, Michallet M, et al: Prior treatment with alpha interferon does not adversely affect the outcome of allogeneic transplantation for chronic myeloid leukaemia. Br J Haematol 116:193-201, 2002
65. Pinilla-Ibarz J, Cathcart K, Scheinberg DA: CML vaccines as a paradigm of the specific immunotherapy of cancer. Blood Rev 14:111-120, 2000
66. Pocock C, Szydlo R, Davis J, et al: Stem cell transplantation for chronic myeloid leukaemia: The role of infused marrow cell dose. Hematol J 2:265-272, 2001
67. Raanani P, Dazzi F, Sohal J, et al: The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol 99:945-950, 1997
68. Radich JP, Gooley T, Bryant E, et al: The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation. Blood 98:1701-1707, 2001
69. Raiola AM, Van Lint MT, Lamparelli T, et al: Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. Br J Haematol 109:716-721, 2000
70. Reiter E, Greinix HT, Keil F, et al: Long-term follow-up of patients after related- and unrelated-donor bone marrow transplantation for chronic myelogenous leukemia. Ann Hematol 78:507-513, 1999
71. Ringden O, Remberger M, Ruutu T, et al: Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: Long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood 93:2196-2201, 1999
72. Robinson SP, Mackinnon S, Slavin S, et al: A retrospective study of non-myeloablative allogeneic stem cell transplantation for lymphoma. Bone Marrow Transplantation 27:65, (suppl 1, abstr)
73. Roman J, Martin C, Torres A, et al: Importance of mixed chimerism to predict relapse in persistently BCR/ABL positive long survivors after allogeneic bone marrow transplantation for chronic myeloid leukemia. Leuk Lymphoma 28:541-550, 1998
74. Ruggeri L, Capanni M, Urbani E, et al: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097-2100, 2002
75. Sandmaier BM, Niederwieser D, McSweeney PA, et al: Induction of molecular remissions in chronic myelogenous leukemia (CML) with nonmyeloablative HLA-identical sibling allografts. Blood 96:201, 2000 (suppl 1, abstr)
76. Schattenberg A, Preijers F, Mensink E, et al: Survival in first or second remission after lymphocyte-depleted transplantation for Philadelphia chromosome-positive CML in first chronic phase. Bone Marrow Transplant 19:1205-1212, 1997
77. Schmitz N, Barrett J: Optimizing engraftment - Source and dose of stem cells. Semin Hematol. 39:3-14, 2002
78. Sehn LH, Alyea EP, Weller E, et al: Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: Impact of donor lymphocyte infusion. J Clin Oncol 17:561-568, 1999
79. Serrano J, Roman J, Sanchez J, et al: Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p21O(BCR-ABL) and pl90(BCR ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: Increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse. Blood 95:2659-2665, 2000
80. Sharathkumar A, Thornley I, Saunders EF, et al: Allogeneic bone marrow transplantation in children with chronic myelogenous leukemia. J Pediatr Hematol Oncol 24:215-219, 2002
81. Siegert W, Beyer J, Kingreen D, et al: Treatment of relapse after allogeneic bone marrow transplantation with unmanipulated G-CSF-mobilized peripheral blood stem cell preparation. Bone Marrow Transplant 22:579-583, 1998
82. Slavin S, Nagler A, Naparstek E, et al: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756-763, 1998
83. Slavin S, Ackerstein A, Morecki S, et al: Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes. Bone Marrow Transplant 28:795-798, 2001
84. Socie G, Clift RA, Blaise D, et al: Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: Long-term follow-up of 4 randomized studies. Blood 98:3569-3574, 2001
85. Speiser DE, Hermans J, van Biezen A, et al: Haploidentical family member transplants for patients with chronic myeloid leukaemia: A report of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 19:1197-1203, 1997
86. Sullivan KM, Weiden PL, Storb R, et al: Influence of acute and chronic graft-versus-host disease after relapse and survival after bone marrow transplantation from HLA identical siblings as treatment of acute and chronic leukemia. Blood 73:1720-722, 1989
87. Szydlo R, Goldman JM, Klein JP, et al: Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 15:1767-1777, 1997
88. Tomas JF, Lopez-Lorenzo JL, Requena MJ, et al: Absence of influence of prior treatment with interferon on the outcome of allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 22:47-51, 1998
89. van Rhee F, Kolb HJ: Donor leukocyte transfusions for leukemic relapse. Curr Opin Hematol 2:423-30, 1995
90. van Rhee F, Szydlo RM, Hermans J, et al: Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: A report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 20:553-560, 1997
91. van Rhee F, Savage D, Blackwell J, et al: Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: Equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant 21:1055-1061, 1998
92. Vela-Ojeda J, Tripp-Villanueva F, Sanchez-Cortes E, et al: Allogeneic bone marrow transplantation for chronic myeloid leukemia: A single center experience. Arch Med Res 31:206-209, 2000
93. Vey N, Balatzentko G, Lafage M, et al: Survey of early disappearance of BCR/ABL fusion transcript after allogeneic or autologous stem cell transplantation for chronic myelogenous leukemia. Leuk Lymphoma 42:945-952, 2001
94. Visani G, Rosti G, Bandini G, et al: Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. Br J Haematol 109:722-728, 2000
95. Warren EH; Greenberg PD; Riddell SR, Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood 91:2197-2207, 1998
96. Weisdorf DJ, Anasetti C, Antin J, et al: Allogeneic bone marrow transplantation for chronic myelogenous leukemia: Comparative analysis of unrelated versus matched sibling donor transplantation. Blood 99:1971-1977, 2002
97. + T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells. Transplantation 71:1131-1137, 2001
98. Zuffa E, Bandini G, Bonini A, et al: Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia. Haematologica 83:231-236, 1998